|
|
Article: CombinatoRx Drops CRx-150, Favors CRx-102 In Arthritis.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
After getting mixed results in a Phase II trial of CRx-150 in rheumatoid arthritis, CombinatoRx Inc. decided to discontinue development of the product and reallocate its funding to CRx-102, which is poised to begin two Phase IIb arthritis studies later this year.
"Getting straight to the point, CRx-150 does not meet our target product profile," CombinatoRx President and CEO Alexis Borisy said during a conference call. "CRx-150's activity is clearly not competitive in the current or future RA marketplace. We also believe we have a much stronger RA candidate with CRx-102," he added.
The decision didn't get much of a reaction from ...